Molly P. Hogan

Molly P. Hogan

Auto-generated profile, based on publicly available information

Molly P. Hogan

Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2015 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
MHMolly P. Hogan
Molly P. Hogan
DGDebra A. Goldman
Debra A. Goldman
BDBrittany Dashevsky
Brittany Dashevsky
CRChristopher Riedl
Christopher Riedl
MGMithat Gönen
Mithat Gönen
GUGary A. Ulaner
Gary A. Ulaner
Although guidelines such as those of the National Comprehensive Cancer Network consider 18F-FDG PET/CT for systemic staging of newly diagnosed stage III breast cancer patients, factors in addition to stage may influence the utility of PET/CT. Because invasive lobular carcinoma (ILC) is less conspicuous than invasive ductal carcinoma (IDC) on 18F-FDG PET, we hypothesized that tumor histology may be one such factor. We evaluated PET/CT systemic staging of patients newly diagnosed with ILC compared with IDC. Methods: In this Institutional Review Board–approved retrospective study, our Hospital Information System was screened for ILC patients who underwent PET/CT in 2006–2013 before systemic or radiation therapy. Initial stage was determined from examination, mammography, ultrasound, MR, or surgery. PET/CT was performed to identify unsuspected distant metastases. A sequential cohort of stage III IDC patients was evaluated for comparison. Upstaging rates were compared using the Pearson χ2 test. Results: The study criteria were fulfilled by 146 ILC patients. PET/CT revealed unsuspected distant metastases in 12 (8%): 0 of 8 with initial stage I, 2 of 50 (4%) stage II, and 10 of 88 (11%) stage III. Upstaging to IV by PET/CT was confirmed by biopsy in all cases. Three of 12 upstaged patients were upstaged only by the CT component of the PET/CT, as the metastases were not 18F-FDG–avid. In the comparison stage III IDC cohort, 22% (20/89) of patients were upstaged to IV by PET/CT. All 20 demonstrated 18F-FDG–avid metastases. The relative risk of PET/CT revealing unsuspected distant metastases in stage III IDC patients was 1.98 times (95% confidence interval, 0.98–3.98) that of stage III ILC patients (P = 0.049). For 18F-FDG–avid metastases, the relative risk of PET/CT revealing unsuspected 18F-FDG–avid distant metastases in stage III IDC patients was 2.82 times (95% confidence interval, 1.26–6.34) that of stage III ILC patients (P = 0.007). Conclusion: 18F-FDG PET/CT was more likely to reveal unsuspected distant metastases in stage III IDC patients than in stage III ILC patients. In addition, some ILC patients were upstaged by non–18F-FDG-avid lesions visible only on the CT images. Overall, the impact of PET/CT on systemic staging may be lower for ILC patients than for IDC patients.

1 June 2025 in Radiology
Verified
Journal Article
Closed access
SESarah Eskreis-Winkler
Sarah Eskreis-Winkler
Arka BhowmikArka Bhowmik
Arka Bhowmik
LKLori H. Kelly
Lori H. Kelly
RGRoberto Lo Gullo
Roberto Lo Gullo
DDDonna D’aLessio
Donna D’aLessio
Katja Pinker-DomenigKatja Pinker-Domenig
Katja Pinker-Domenig
Image-based artificial intelligence triage could be used to make modifications to breast MRI scanning protocols in real time, ensuring that sufficient diagnostic information is obtained for each patient as quickly as possible.

1 December 2016 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
MHMolly P. Hogan
Molly P. Hogan
JOJoseph Osborne
Joseph Osborne
GUGary A. Ulaner
Gary A. Ulaner
Intrathecal methotrexate is a standard option for central nervous system–directed therapy in patients with stage III and IV diffuse large B-cell lymphoma. We present a case of a 50-year-old man with stage IV diffuse large B-cell lymphoma with widespread lymphomatous involvement including the central nervous system, who received 7 doses of intrathecal methotrexate via Ommaya catheter. Posttherapy 18F-FDG-PET/CT imaging demonstrated diffuse, intense intrathecal FDG avidity, without correlative findings on MR spinal imaging. FDG avidity resolved on follow-up. These PET/CT findings are most consistent with methotrexate-induced thecal inflammation, which needs to be distinguished from intrathecal malignancy.

1 May 2026 in Radiology: Imaging Cancer
Verified
Journal Article
Closed access
TATali Amir
Tali Amir
CLCarol H. Lee
Carol H. Lee
SESarah Eskreis-Winkler
Sarah Eskreis-Winkler
MHMolly P. Hogan
Molly P. Hogan
NNNoam Nissan
Noam Nissan
JSJanice S. Sung
Janice S. Sung
In patients undergoing screening contrast-enhanced mammography, the interval cancer rate was 2.29 cancers per 1000 examinations, and invasive interval cancers were associated with moderate or marked background parenchymal enhancement.